

# Chapter 156

## Dermatomyositis

Richard D. Sontheimer,  
Christopher B. Hansen & Melissa I. Costner

### REFERENCES

1. Sontheimer RD: Cutaneous features of classical dermatomyositis and amyopathic dermatomyositis. *Curr Opin Rheumatol* 11:475, 1999
2. Sontheimer RD: Would a new name hasten the acceptance of clinically-amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? *J Am Acad Dermatol* 46:626, 2002
3. Sontheimer RD: Lupus erythematosus and dermatomyositis. *Curr Prob Dermatol* 12:5, 2000
4. Sontheimer RD, Costner MI: Dermatomyositis. In: *Fitzpatrick's Dermatology in General Medicine*, 6th edition, edited by IM Freedberg et al. New York, McGraw-Hill, 2003, p. 1694
5. Sontheimer RD et al: Dermatomyositis. In: *Cutaneous Manifestations of Rheumatic Diseases*, 2nd edition, edited by RD Sontheimer, TT Provost. Baltimore, Williams & Wilkins, 2004, p. 65
6. Caro I: Dermatomyositis. *Semin Cutan Med Surg* 20:38, 2001
7. Rendt K: Inflammatory myopathies: Narrowing the differential diagnosis. *Cleve Clin J Med* 68:505, 2001
8. Koler RA, Montemarano A: Dermatomyositis. *Am Fam Physician* 64:1565, 2001
9. Reed AM: Myositis in children. *Curr Opin Rheumatol* 13:428, 2001
10. Callen JP: Dermatomyositis. *Lancet* 355:53, 2000
11. Rider LG, Miller FW: Idiopathic inflammatory muscle disease: Clinical aspects. *Baillieres Best Pract Res Clin Rheumatol* 14:37, 2000
12. Rider LG et al: Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum* 41:710, 1998
13. Kovacs SO, Kovacs SC: Dermatomyositis. *J Am Acad Dermatol* 39:899, 1998
14. Olsen NJ, Park JH: Inflammatory myopathies: Issues in diagnosis and management. *Arthritis Care Res* 10:200, 1997
15. Jorizzo JL: Dermatomyositis—Practical aspects. *Arch Dermatol* 138:114, 2002
16. Callen JP: Dermatomyositis: Diagnosis, evaluation and management. *Minerva Med* 93:157, 2002
17. Oddis CV et al: Incidence of polymyositis-dermatomyositis: a 20 year study of hospital based cases in Allegheny County, PA 1963-1982. *J Rheumatol* 10:1329-1334, 1990
18. Mendez EP et al: US incidence of juvenile dermatomyositis, 1995–1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. *Arthritis Rheum* 49:300, 2003
19. Sontheimer RD: Clinically amyopathic dermatomyositis: what can we now tell our patients? *Arch Dermatol* 146(1):76-80, 2010
20. Gerami P et al: A systematic review of juvenile-onset clinically-amyopathic dermatomyositis (dermatomyositis sine myositis). *157(4):637-644*, 2007
21. Marie I et al: Pseudo-dermatomyositis as a complication of hydroxyurea therapy. *Clin Exp Rheumatol* 18:536, 2000
22. Price P et al: The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. *Immunol Rev* 167:257, 1999
23. Pachman LM et al: TNFalpha-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. *Arthritis Rheum* 43:2368, 2000
24. Werth VP et al: Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. *J Invest Dermatol* 119:1394, 2002
25. Caproni M et al: Amyopathic dermatomyositis. A review by the Italian Group of Immunodermatology. *Arch Dermatol* 138:23, 2002
26. Ang P et al: Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: A 3-year retrospective review of their clinical characteristics and association with malignancy. *Ann Acad Med Singapore* 29:219, 2000
27. Chen YJ et al: Predicting factors of malignancy in dermatomyositis and polymyositis: A case-control study. *Br J Dermatol* 144:825, 2001

28. Arnett FC et al: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. *Arthritis Rheum* **39**:1507, 1996
29. Gerami P et al: A systematic review of adult-onset clinically-amyopathic dermatomyositis: A missing link in the spectrum of the idiopathic inflammatory myopathies. *J Am Acad Dermatol* **54**:597, 2006
30. Peloro TM et al: Juvenile dermatomyositis: A retrospective review of a 30-year experience. *J Am Acad Dermatol* **45**:28, 2001
31. Dourmishev AL, Dourmishev LA: Dermatomyositis and drugs. *Adv Exp Med Biol* **455**:187, 1999
32. Vasconcelos OM, Campbell WW: Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. *Muscle Nerve* **30**(6):803-807, 2004
33. Seidler AM, Gottlieb AB: Dermatomyositis induced by drug therapy: A review of case reports. *J Am Acad Dermatol* **59**(5):872-880, 2008. [Epub 2008 Jul 14.]
34. Werth VP et al: Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. *J Invest Dermatol* **115**:726
35. Mamyrova G et al: Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis Rheum* **58**(12):3941-3950, 2008
36. Ichikawa E et al: Hereditary complement (C9) deficiency associated with dermatomyositis. *Br J Dermatol* **144**:1080, 2001
37. Okada S et al: Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis Rheum* **48**:2285, 2003
38. Love LA et al: Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. *Arthritis Rheum* **60**(8):2499-2504, 2009
39. Targoff IN et al: Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis. *Arthritis Rheum* **43**:S194, 2000
40. Sato S et al: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. *Arthritis Rheum* **52**:1571, 2005
41. Bank I et al: Mechanisms of cell-mediated myocytotoxicity in the peripheral blood of patients with inflammatory myopathies. *J Clin Immunol* **21**:328, 2001
42. Lundberg IE: Idiopathic inflammatory myopathies: Why do the muscles become weak? *Curr Opin Rheumatol* **13**:457, 2001
43. Reed AM et al: Chimerism in children with juvenile dermatomyositis. *Lancet* **356**:2156, 2000
44. Magro CM, Crowson AN: The immunofluorescent profile of dermatomyositis: A comparative study with lupus erythematosus. *J Cutan Pathol* **24**:543, 1997
45. Dourmishev LA, Wollina U: Dermatomyositis: Immunopathologic study of skin lesions. *Acta Dermatovenerol Alp Panonica Adriat* **15**:45, 2006
46. Tezak Z et al: Gene expression profiling in DQA1\*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. *J Immunol* **168**:4154, 2002
47. Greenberg SA et al: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. *Ann Neurol* **57**:664, 2005
48. Wenzel J et al: Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. *Clin Exp Dermatol* **31**:576, 2006
49. Tominaga A et al: Reticular erythematous mucinosis syndrome with an infiltration of factor XIIIa+ and hyaluronan synthase 2+ dermal dendrocytes. *Br J Dermatol* **145**:141, 2001
50. Sontheimer RD: Dermatomyositis. An overview of recent progress with emphasis on dermatological aspects. *Clin Dermatol* **20**:387, 2002
51. Shibuya H et al: Three cases of "mechanic's hands" associated with interstitial pneumonia: Possible involvement with foot lesions. *J Dermatol* **30**:892, 2003
52. Watanabe C et al: A case of dermatomyositis associated with mechanic's hand. *J Dermatol* **27**:711, 2000
53. Plastiras SC et al: Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. *Clin Rheumatol* **26**:108, 2007; Epub Nov 23, 2005
54. Hundley JL et al: Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. *J Am Acad Dermatol* **54**:217, 2006
55. Kimball AB et al: Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum* **43**:1866, 2000
56. Kasteler JS, Callen JP: Scalp involvement in dermatomyositis: Often overlooked and misdiagnosed. *JAMA* **272**:1939, 1994

57. Lupton JR et al: An unusual presentation of dermatomyositis: The type Wong variant revisited. *J Am Acad Dermatol* **43**:908, 2000
58. Wong KO: Dermatomyositis: A clinical investigation of 23 cases in Hong Kong. *Br J Dermatol* **81**:544, 1969
59. Huemer C et al: Lipodystrophy in patients with juvenile dermatomyositis—Evaluation of clinical and metabolic abnormalities. *J Rheumatol* **28**:610, 2001
60. Rider L et al: Lipodystrophy in juvenile dermatomyositis is associated with calcinosis, but not with hepatocyte differentiation factor DLK levels. *Arthritis Rheum* **44**:S264, 2001
61. Ghali FE et al: Gingival telangiectases: An underappreciated physical sign of juvenile dermatomyositis. *Arch Dermatol* **135**:1370, 1999
62. Del Pozo J et al: Dermatomyositis and mucinosis. *Int J Dermatol* **40**:120, 2001
63. el-Azhary R, Pakzad SY: Amyopathic dermatomyositis: Retrospective review of 37 cases. *J Am Acad Dermatol* **46**:560, 2002
64. Thune P: The coexistence of amyopathic dermatomyositis and fibromyalgia. *Acta Derm Venereol* **80**:453, 2000
65. Plamondon S, Dent PB: Juvenile amyopathic dermatomyositis: Results of a case-finding descriptive survey. *J Rheumatol* **27**:2031, 2000
66. Eisenstein DM et al: Juvenile dermatomyositis presenting with rash alone. *Pediatrics* **100**:391, 1997
67. Hirakata M, Nagai S: Interstitial lung disease in polymyositis and dermatomyositis. *Curr Opin Rheumatol* **12**:501, 2000
68. Douglas WW et al: Polymyositis-dermatomyositis-associated interstitial lung disease. *Am J Resp Crit Care Med* **164**:1182, 2001
69. Friedman AW et al: Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. *Semin Arthritis Rheum* **26**:459, 1996
70. al-Mayouf SM et al: Cyclosporine in the treatment of an unusual case of juvenile systemic sclerosis. *J Rheumatol* **25**:791, 1998
71. Sontheimer RD, Miyagawa S: Potentially-fatal interstitial lung disease presenting in the context of amyopathic dermatomyositis [letter]. *J Am Acad Dermatol* **48**:797, 2003
72. Suda T et al: Interstitial lung diseases associated with amyopathic dermatomyositis. *Eur Respir J* **28**:1005, 2006; Epub Jul 12, 2006
73. Mukae H et al: Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. *Chest* **136**(5):1341-1347, 2009. [Epub 2009 Jul 6.]
74. Kameda H et al: Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. *J Rheumatol* **32**:1719, 2005
75. Tse S et al: The arthritis of inflammatory childhood myositis syndromes. *J Rheumatol* **28**:192
76. Sontheimer RD: A portable digital microphotography unit for rapid documentation of periungual nailfold capillary changes in autoimmune connective tissue diseases. *J Rheumatol* **31**:539, 2004
77. Targoff IN: Update on myositis-specific and myositis-associated autoantibodies. *Curr Opin Rheumatol* **12**:475, 2000
78. Brouwer R et al: Autoantibody profiles in the sera of European patients with myositis. *Ann Rheum Dis* **60**:116, 2001
79. Chinoy H et al: The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. *Ann Rheum Dis* **66**(10):1345-1349, 2007
80. Hirakata M, Nagai S: Interstitial lung disease in polymyositis and dermatomyositis. *Curr Opin Rheumatol* **12**:501, 2000
81. Sontheimer RD et al: Autoantibodies to 155 kd and Se antigens in patients with clinically amyopathic dermatomyositis. *J Invest Dermatol* **117**:466, 2001
82. Sato S et al: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. *Arthritis Rheum* **52**(5):1561-1566, 2005
83. Sato S et al: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. *Arthritis Rheum* **60**(7):2193-2200, 2009
84. Kubo M et al: Serum KL-6 in adult patients with polymyositis and dermatomyositis. *Rheumatology (Oxford)* **39**:632, 2000
85. Fall N et al: Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: Possible link to vasculopathy. *Arthritis Rheum* **52**:3175, 2005

86. Park JH, Olsen NJ: Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. *Curr Rheumatol Rep* 3:334, 2001
87. Meng C et al: Combined use of power Doppler and gray-scale sonography: A new technique for the assessment of inflammatory myopathy. *Rheumatology* 28:1271, 2001
88. Park JH et al: Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis. *NMR Biomed* 11:245, 1998
- 89 **Rendt K: Inflammatory myopathies: Narrowing the differential diagnosis.** *Clev Clin J Med* 68:505, 2001
90. Sigurgeirsson B et al: Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. *N Engl J Med.* 326:363, 1992
- 91 **Airio A et al: Elevated cancer incidence in patients with dermatomyositis: A population based study.** *J Rheumatol* 22:1300, 1995
92. Leow YH, Goh CL: Malignancy in adult dermatomyositis. *Int J Dermatol* 36:904, 1997
93. Yazici Y, Kagen LJ: The association of malignancy with myositis. *Curr Opin Rheumatol* 12:498, 2000
94. Stockton D et al: Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. *Br J Cancer* 85:41, 2001
95. Morris P, Dare J: Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. *J Pediatr Hematol Oncol* 32(3):189-191, 2010.
96. Juarez M, Misischia R, Alarcon GS: Infections in systemic connective tissue diseases: Systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. *Rheum Dis Clin North Am* 29:163, 2003
97. Waldman MA, Callen JP: Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. *J Am Acad Dermatol* 51:S124, 2004
98. Hochberg MC et al: Mortality from polymyositis and dermatomyositis in the United States. 1968-1978. *Arthritis Rheum* 26:1465-1471, 1983
99. Maire I et al: Polymyositis and Dermatomyositis: short term and long term outcome, and predictive factors of prognosis. *J Rheumatol* 28(10):2230-2237, 2001
100. Danko K et al: Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features—A longitudinal study of 162 cases. *Medicine (Baltimore)* 83:35, 2004
101. Krain L: Dermatomyositis in six patients without initial muscle involvement. *Arch Dermatol* 110:241, 1975
102. Euwer RL, Sontheimer RD: Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. *J Am Acad Dermatol* 24:959, 1991
103. Yassaee M et al: Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. *Br J Dermatol* 162(3):669-673, 2010. [Epub 2009 Oct 26.]
104. Ting WW, Sontheimer RD: Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations. *Lupus* 10:171, 2001
105. Yanagi T et al: Treatment for poikilodermatous erythema of dermatomyositis with the pulsed dye laser. *Br J Dermatol* 153:862, 2005
106. Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. *Arch Dermatol* 138:1231, 2002
107. Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study. *Arch Dermatol* 141:855, 2005
108. Cohen JB: Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. *Int J Dermatol* 41:182, 2002
109. Konohana A, Kawashima J: Successful treatment of dermatomyositis with dapsone. *Clin Exp Dermatol* 19:367, 1994
110. Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. *Arch Dermatol* 142:70, 2006
111. Ozawa Y et al: Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. *Ryumachi* 40:798, 2000
112. Takashi S et al: Amyopathic dermatomyositis with interstitial pneumonia: Effective treatment with cyclophosphamide pulse therapy. *Nihon Kokyuki Gakkai Zasshi* 37:647, 1999
113. Edge JC et al: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. *Arch Dermatol* 142(1):65-69, 2006

114. Morganroth PA, Kreider ME, Werth VP: Mycophenolate mofetil for interstitial lung disease in dermatomyositis. *Arthritis Care Res (Hoboken)* **62**(10):1496-1501, 2010
115. Keystone EC: The utility of tumour necrosis factor blockade in orphan diseases. *Ann Rheum Dis* **63**:79, 2004
116. Rios Fernández R et al: Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. *Clin Exp Rheumatol* **27**(6):1009-1016, 2009
117. Levine TD: Rituximab in the treatment of dermatomyositis: An open-label pilot study. *Arthritis Rheum* **52**:601, 2005
118. Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. *J Rheumatol* **33**:1021, 2006
119. Mukamel M et al: New insight into calcinosis of juvenile dermatomyositis: A study of composition and treatment. *J Pediatr* **138**:763, 2001
120. Bruculeri M et al: Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. *Semin Dial* **18**:431, 2005
121. Cicone JS et al: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. *Am J Kidney Dis* **43**:1104, 2004
122. Chan AY, Li E: Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis—Old method, new discovery. *Clin Rheumatol* **24**:172, 2005
123. Cosentino R et al: Extracorporeal shock wave therapy for chronic calcific tendinitis of the shoulder: Single blind study. *Ann Rheum Dis* **62**:248, 2003
124. Plamondon S, Dent PB: Juvenile amyopathic dermatomyositis: Results of a case finding descriptive survey. *J Rheumatol* **27**:2031, 2000
125. Schmid MH, Trueb RM: Juvenile amyopathic dermatomyositis. *Br J Dermatol* **136**:431, 1997
126. Euwer RL, Sontheimer RD: Amyopathic dermatomyositis: A review. *J Invest Dermatol* **10**:124S, 1993
127. Marie I et al: Polymyositis and dermatomyositis: Short-term and long-term outcome, and predictive factors of prognosis. *J Rheumatol* **28**:2230, 2001

